Results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study were released at a session at the 9th South African AIDS Conference (SA AIDS 2019) in Durban, South Africa, on Thursday, June 13th. The session, which included presentations on the primary analysis, was recorded and can be viewed on YouTube here.
Data use
Event
June 13, 2019
Resource
June 13, 2019
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label randomised clinical trial comparing three highly effective, reversible methods of contraception — a progestogen-only injectable called depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.Read this fact sheet for more about the ECHO study.
Resource
May 6, 2019
The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships.
Resource
April 12, 2019
In East and Southern Africa, where 5% to 10% have chronic hepatitis B virus (HBV) infection, incidence of human immunodeficiency virus (HIV) infection remains unacceptably high. This introduces challenges and opportunities for implementation of HBV care and treatment.
Resource
April 12, 2019
The aim of the study was to investigate the extent of and factors associated with incorrect dosing of antiretroviral therapy (ART) in HIV-infected children in Harare, Zimbabwe.
Resource
April 12, 2019
Treat-all is being implemented in several African settings, in accordance with 2015 World Health Organisation guidelines. The factors known to undermine adherence to antiretroviral therapy (ART) may change in the context of Treat-all, where people living with HIV (PLHIV) increasingly initiate ART at earlier, asymptomatic stages of disease, soon after diagnosis. This paper aimed to examine the asymptomatic PLHIV's experiences engaging with early ART initiation under the Treat-all policy, including how they navigate treatment-taking over the longer term.
Resource
April 2, 2019
TB Data, Impact Assessment and Communications Hub (TB DIAH) is a new project that just launched a web-based, interactive data platform for global tuberculosis (TB) data users. TB DIAH is associated with the Global Accelerator to End TB, USAID’s new business model to focus on per
Resource
March 19, 2019
The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) delivers life-saving services to people affected by the HIV/AIDS epidemic in 36 country and regional programs. Founded in 2003, PEPFAR is the largest investment in combating a single disease by a single country in history.
Resource
February 27, 2019
Information from community-based health programs is important for understanding what HIV programs are doing to test, treat, and retain in care people who are living with HIV.
